ADMA Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADMA research report →
About the company
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
- CEO
- Adam S. Grossman
- IPO
- 2013
- Employees
- 685
- HQ
- Ramsey, NJ, US
Price Chart
- Market Cap
- $2.07B
- P/E
- 12.78
- P/S
- 4.07
- P/B
- 5.41
- EV/EBITDA
- 9.66
- Div Yield
- 0.00%
- Gross Margin
- 61.27%
- Op Margin
- 40.57%
- Net Margin
- 32.43%
- ROE
- 38.97%
- ROIC
- 27.81%
- Revenue
- $510.17M · 19.63%
- Net Income
- $146.93M · -25.67%
- EPS
- $0.62 · -27.06%
- Op Income
- $191.44M
- FCF YoY
- -74.73%
- 52W High
- $20.46
- 52W Low
- $7.21
- 50D MA
- $8.83
- 200D MA
- $13.98
- Beta
- 0.73
- Avg Volume
- 5.23M
Get TickerSpark's AI analysis on ADMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | Grossman Jerrold B | buy | 6,400 |
| May 12, 26 | Grossman Jerrold B | buy | 12,500 |
| May 11, 26 | Grossman Jerrold B | buy | 12,500 |
| Apr 1, 26 | Kestenberg-Messina Kaitlin M. | other | 20,362 |
| Mar 13, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 17, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 17, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 13, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 16, 26 | Grossman Adam S | other | 15,000 |
| Mar 16, 26 | Grossman Adam S | sell | 15,000 |
Our ADMA coverage
Recent articles, reports, and earnings notes.
No research on ADMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADMA report →Similar companies
Peers in the same neighborhood.